FOLH1 and prostate carcinoma: PSMA is a membrane glycoprotein that is highly and selectively expressed in prostate cancer, and a PSMA ADC using an MMAE payload and valine-citrulline dipeptide linker has shown safety and activity in phase I trials [124].